Literature DB >> 7307430

Antipyrine and warfarin disposition in a patient with idiopathic hypoalbuminemia.

R J Piroli, G T Passananti, C A Shively, E S Vesell.   

Abstract

In a subject with the rare condition of idiopathic hypoalbuminemia, antipyrine and warfarin disposition was investigated to determine whether, in an otherwise healthy subject, low albumin concentrations affect the kinetics of these prototypic drugs. Because antipyrine is negligibly bound to albumin its disposition would be expected to be normal, but because at usual therapeutic doses warfarin is 99% bound to albumin, warfarin elimination would be expected to be accelerated in idiopathic hypoalbuminemia. In our patient antipyrine disposition was normal, whereas warfarin clearance was increased and plasma warfarin half-life reduced. The apparent volume of distribution of warfarin was within normal range. Warfarin binding to the patient's plasma was decreased; the free fraction of warfarin in plasma was correspondingly elevated. Albumin isolated from the patient and purified exhibited kinetic values for warfarin binding. Caution is necessary in extending these results to other drugs and other patients with idiopathic hypoalbuminemia since the validity of such extrapolations depends on the extent to which the drug investigated is normally bound to albumin and also on the magnitude of the particular patient's hypoalbuminemia at the precise time of study.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7307430     DOI: 10.1038/clpt.1981.242

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  4 in total

1.  Personalized prophylactic anticoagulation decision analysis in patients with membranous nephropathy.

Authors:  Taewoo Lee; Andrea K Biddle; Sofia Lionaki; Vimal K Derebail; Sean J Barbour; Sameer Tannous; Michelle A Hladunewich; Yichun Hu; Caroline J Poulton; Shannon L Mahoney; J Charles Jennette; Susan L Hogan; Ronald J Falk; Daniel C Cattran; Heather N Reich; Patrick H Nachman
Journal:  Kidney Int       Date:  2013-12-11       Impact factor: 10.612

Review 2.  Clinical pharmacokinetics and pharmacodynamics of warfarin. Understanding the dose-effect relationship.

Authors:  N H Holford
Journal:  Clin Pharmacokinet       Date:  1986 Nov-Dec       Impact factor: 6.447

3.  Analbuminemia.

Authors:  E Russi; K Weigand
Journal:  Klin Wochenschr       Date:  1983-06-01

Review 4.  Clinical pharmacokinetic considerations in the control of oral anticoagulant therapy.

Authors:  H G Shetty; A G Fennerty; P A Routledge
Journal:  Clin Pharmacokinet       Date:  1989-04       Impact factor: 6.447

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.